ZBH Zimmer Biomet

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model not detailed in this section; focuses on corporate governance and compliance policies
• • Adoption of Zimmer Biomet Code of Ethics for CEO and senior financial officers, publicly accessible online
• • Implementation of insider trading policy for directors, senior management, and employees, included as exhibit in 10-K
• • Corporate governance and executive compensation details incorporated by reference from 2026 Proxy Statement
• • No new products, services, or strategic shifts disclosed within this filing's Business section

Risk Factors

• • Cybersecurity risk oversight by Audit Committee with immediate escalation of material incidents to board
• • Potential operational disruption from evolving global cybersecurity threats monitored by specialized global security team
• • Cybersecurity incident review managed by cross-functional subcommittee including info security, legal, accounting, internal audit
• • Leadership by VP CISO with 30+ years IT security experience driving cybersecurity program and reporting to Audit Committee
• • Security operations team includes advanced degree and certified professionals supporting ongoing cybersecurity enhancements

Management Discussion & Analysis

• • Revenue $8,231.5M in 2025, up 7.2% YoY from $7,678.6M, driven by Paragon 28 acquisition (+2.5%), market growth, and currency effects (+0.8%)
• • Operating margin 13.3% in 2025 vs 16.7% in 2024, decline due to inventory charges (~$170M), acquisition/integration costs, tariffs, and higher compensation
• • Best segment Americas: operating profit $2,645.7M (51.4% of sales), worst Asia Pacific: operating profit $446.0M (35.5% margin), both margins down YoY
• • Operating cash flow $1,697.1M up from $1,499.4M; investing cash outflow $1,975.7M mainly for acquisitions ($1,393.2M); financing cash inflow $326.0M with $487M share buybacks and dividend payments of $0.24/share quarterly
• • 2026 outlook: net sales growth 2.5%-4.5%, operating profit to increase YoY; risks include inflation, interest expense, effective tax rate increase, and go-to-market execution changes

What are the latest ZBH SEC filings in 2026?

Zimmer Biomet (ZBH) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on May 1, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ZBH file its most recent 10-K annual report?

Zimmer Biomet (ZBH) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ZBH 10-Q quarterly reports?

Zimmer Biomet (ZBH)'s most recent 10-Q quarterly report was filed on May 1, 2026. SignalX displays every ZBH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ZBH filed recently?

Zimmer Biomet (ZBH)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ZBH insider trading activity (Form 4)?

SignalX aggregates every ZBH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ZBH file with the SEC?

Zimmer Biomet (ZBH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ZBH filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Zimmer Biomet (ZBH).

What is ZBH's SEC CIK number?

Zimmer Biomet (ZBH)'s SEC CIK (Central Index Key) number is 1136869. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1136869 to look up all ZBH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ZBH return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Zimmer Biomet (ZBH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.